KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) EBT (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed EBT for 17 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 740.0% to $1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $9.3 billion, a 211.33% increase, with the full-year FY2025 number at $9.3 billion, up 211.33% from a year prior.
  • EBT was $1.5 billion for Q4 2025 at Bristol Myers Squibb, down from $3.1 billion in the prior quarter.
  • In the past five years, EBT ranged from a high of $3.1 billion in Q3 2025 to a low of -$11.5 billion in Q1 2024.
  • A 5-year average of $1.3 billion and a median of $1.9 billion in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 932.24% in 2021, then tumbled 515.74% in 2024.
  • Bristol Myers Squibb's EBT stood at $1.9 billion in 2021, then increased by 0.05% to $1.9 billion in 2022, then decreased by 9.95% to $1.7 billion in 2023, then plummeted by 89.55% to $175.0 million in 2024, then soared by 740.0% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's EBT are $1.5 billion (Q4 2025), $3.1 billion (Q3 2025), and $1.8 billion (Q2 2025).